IRVINE, Calif., July 23, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) announced today that MWI Veterinary Supply, Inc. (NASDAQ: MWIV), one of the largest national distributors of medical supplies and equipment to veterinarians, will for the first time distribute Masimo products.
Masimo's Radical-7® Pulse CO-Oximeter with upgradable rainbow® technology and Masimo's handheld Rad-5® and portable Rad-8® with SET Measure-through Motion and Low Perfusion pulse oximetry will be available to MWI's U.S. customer base of veterinarians and animal healthcare providers in all 50 states.
"Veterinarians understand Masimo's breakthrough pulse oximetry technology delivers accurate measurements, even during patient movement and low perfusion," said Kristin Krawczyk, MWI National Equipment Program Manager. "We look forward to working with Masimo to expand its reach into the veterinary market and to meet the upsurge in demand for its breakthrough pulse oximetry technology."
The American Pet Products Association estimates that 62% of all U.S. households – about 73 million homes – own a pet. Veterinary Pet Insurance Co. (VPI) reports that nationwide, its policyholders spent more than $46 million in 2011 treating the 10 most common medical conditions afflicting their pets. Masimo's technology is designed to provide clinicians oxygen saturation (SpO2) measurements under the most challenging conditions – patient motion and low perfusion, which are common in animal healthcare. Masimo SET® virtually eliminates false alarms1 and increases a clinician's ability to detect life-threatening events.2
"Masimo pulse oximeters have far fewer drop-offs and subsequent false alarms in post-op," said Bob Klostermann, a veterinarian and consultant at the University of Wisconsin, Madison. "Masimo's equipment works consistently and gives the entire staff and surgeon a lot more peace of mind with consistent, accurate readings and minimal drop-off alarms."
"As one of the largest and most respected distributors of animal health products in the nation, MWI offers Masimo an opportunity to better reach veterinarians," said Masimo Director of Strategic Marketing, Alternate Care, Gary Marston. "Animal healthcare represents an important and growing business for Masimo, and we look forward to working with MWI to help clinicians improve outcomes for their four-legged, feathered and reptilian patients."
(1) Shah N, Ragaswamy H, Govindugari K, Estanol L. "Performance of three new-generation pulse oximeters during motion and low perfusion in volunteers." Journal of Clinical Anesthesia. 2012 (10.1016/j.jclinane.2011.10.012) Available online here (2) Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here
About MWI Veterinary Supply, Inc. MWI is a leading distributor of animal health products across the United States of America and United Kingdom. MWI sells both companion animal and production animal products including pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, supplies, pet food, capital equipment and nutritional products. MWI also is a leading innovator and provider of value-added services and technologies used by veterinarians and producers. For more information about MWI, please visit www.mwivet.com.
About Masimo Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, the company introduced Masimo Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET and Masimo rainbow SET technologies can also be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions of the repeatability of clinical results obtained using the new Masimo Pronto-7 and noninvasive sensor sizes, risks related to our belief that the Pronto-7 enables quick and easy noninvasive spot-checking of hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index at the point-of-care for all patients, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.